12:47 Thu 09 Jul 2020
e-Therapeutics plc - Exercise of Broker Option
THIS ANNOUNCEMENT, INCLUDING THE APPENDICES AND THE INFORMATION CONTAINED IN THEM, IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION, DISTRIBUTION OR FORWARDING, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO
THIS ANNOUNCEMENT IS FOR INFORMATION PURPOSES ONLY AND DOES NOT CONSTITUTE OR CONTAIN ANY INVITATION, SOLICITATION, RECOMMENDATION, OFFER OR ADVICE TO ANY PERSON TO SUBSCRIBE FOR, OTHERWISE ACQUIRE OR DISPOSE OF ANY SECURITIES IN E-THERAPEUTICS PLC OR ANY OTHER ENTITY IN ANY SUCH JURISDICTION. PLEASE SEE THE IMPORTANT NOTICES AT THE END OF THIS ANNOUNCEMENT.
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF THE MARKET ABUSE REGULATION (EU) NO. 596/2014.
e-therapeutics plc
("e-therapeutics" or the "Company")
Exercise of Broker Option
e-therapeutics plc (AIM: ETX.L, "e-therapeutics'" or "the Company"), announces that further to the Fundraise announced on
The Broker Option Shares are being issued at a price of 12p per share (being the Placing Price) and will be issued on the same terms and conditions as the Firm Placing Shares pursuant to the Placing.
Application will be made to the
Following the exercise of the Broker Option in respect of 11,204,165 Broker Option Shares, there remains a total of up to 9,629,168 new Ordinary Shares still to be exercised under the Broker Option ahead of the option period ending at
The Company has received advance assurance from
Following the admission of the Firm Placing Shares, Subscription Shares, Retail Shares and the 11,204,165 Broker Option Shares, the Company will have a total of 416,149,611 Ordinary Shares in issue.
Capitalised terms used in this announcement have the meanings given to them in the announcement of the Fundraise dated
For further information, please contact:
e-therapeutics plc
|
Tel: +44 (0)1993 883 125
|
| Tel: +44 (0) 207 260 1000
|
FTI Consulting | Tel: +44 (0) 203 727 1000 Email: |
About e-therapeutics plc
e-therapeutics plc is an
e-therapeutics has developed an in silico laboratory that enables the rapid screening of millions of compounds and the identification of small sub-sets that are enriched for highly active hits. Its proprietary platform also has novel applications in functional genomics, being able to analyse complex genetic datasets, provide a deep understanding of pathological mechanisms and distil actionable insights for the discovery of novel drugs, biomarkers and diagnostics.
e-therapeutics has deployed and validated its disease-agnostic drug discovery platform both in house and with partners, including Novo Nordisk, Galapagos NV and a US-based, top 5 pharmaceutical company.
IMPORTANT NOTICES
No action has been taken by the Company, Numis, or any of their respective affiliates, that would, or which is intended to, permit a public offer of the new Ordinary Shares in any jurisdiction or the possession or distribution of this announcement or any other offering or publicity material relating to the new Ordinary Shares in any jurisdiction where action for that purpose is required. Any failure to comply with these restrictions may constitute a violation of the securities laws of such jurisdictions. Persons into whose possession this announcement comes shall inform themselves about, and observe, such restrictions.
No prospectus will be made available in connection with the matters contained in this announcement and no such prospectus is required (in accordance with the Prospectus Directive) to be published.
THIS ANNOUNCEMENT, INCLUDING THE INFORMATION CONTAINED HEREIN, IS FOR INFORMATION PURPOSES ONLY, IS NOT INTENDED TO AND DOES NOT CONSTITUTE OR FORM PART OF ANY OFFER OR INVITATION TO PURCHASE OR SUBSCRIBE FOR, UNDERWRITE, SELL OR ISSUE OR THE SOLICITATION OF AN OFFER TO PURCHASE OR SUBSCRIBE, SELL, ACQUIRE, DISPOSE OF THE NEW ORDINARY SHARES OR ANY OTHER SECURITY IN
Numis, which is authorised and regulated in the
No representation or warranty, express or implied, is or will be made as to, or in relation to, and no responsibility or liability is or will be accepted by Numis or the Company or any of their respective affiliates or any of their respective directors, officers, employees, advisers or representatives (collectively, "Representatives") as to or in relation to the accuracy or completeness of this announcement or any other written or oral information made available to or publicly available to any interested party or its advisers, and any liability therefor is expressly disclaimed.
This announcement does not identify or suggest, or purport to identify or suggest, the risks (direct or indirect) that may be associated with an investment in the new Ordinary Shares. Any investment decision to buy new Ordinary Shares in the Placing must be made solely on the basis of publicly available information, which has not been independently verified by Numis. The price of Ordinary Shares and any income from them may go down as well as up and investors may not get back the full amount invested on disposal of the Ordinary Shares. The new Ordinary Shares will not be admitted to trading on any stock exchange other than AIM, a market operated by the
This information is provided by RNS, the news service of the
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
FOR OUR FULL DISCLAIMER CLICK HERE